State Initiatives | Association for Accessible Medicines

State Initiatives

A Generic Summer Savings Tour: How Did Your State Do?

The 11th edition of the Association for Accessible Medicines' annual Access and Savings Report (see summary) reveals how much money American patients and taxpayers saved in 2018 through competition from generic drugs and biosimilar alternatives to brand-name biologic medicines. The report provides data by state, based on findings by IQVIA. We’re releasing a detailed publication later this summer.

Some notable facts from the state data:

AAM Statement on U.S. Court of Appeals Ruling on Maryland HB 631

WASHINGTON, DC (April 13, 2018) — Today, the United States Court of Appeals for the Fourth Circuit ruled that Maryland’s HB 631 is unconstitutional because it violates the Commerce Clause of the U.S. Constitution. As AAM has always maintained, this law, and any others modeled from it, would harm patients because the law would reduce generic drug competition and choice, thus resulting in an overall increase in drug costs due to increased reliance upon more-costly branded medications.

Chester "Chip" Davis, Jr. President and CEO, Association for Accessible Medicines

Oppose Illinois House Bill 4900

Everyone supports containing skyrocketing prescription drug prices but HB 4900, sponsored by Rep. Will Guzzardi (D-Chicago), would actually just make the problem worse for Illinois patients. Price gouging– targeted by this bill – is unacceptable. But we must employ sound public policy to both weed out bad apples and enhance a market where they cannot take seed. HB 4900 fails to do either.

Subscribe to State Initiatives

Association for Accessible Medicines

202.249.7100

Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.